Stay updated on Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.
Latest updates to the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check11 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference1.0%
- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check47 days agoChange DetectedThe website has been updated from version v2.12.2 to v2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check62 days agoChange DetectedThe website has added new features for data download options, while several key government health-related URLs and detailed data fields for studies have been removed.SummaryDifference14%
- Check69 days agoChange DetectedNew additions include several key health and government websites, such as HHS, NIH, and NLM, enhancing the site's resource offerings.SummaryDifference0.7%
Stay in the know with updates to Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-CD38 CAR-T in Relapsed/Refractory Multiple Myeloma Clinical Trial page.